文献速递乳腺癌

新辅助buparlisib联合曲妥珠单抗和紫杉醇治疗HER2阳性原发性乳腺癌:随机双盲安慰剂对照II期试验(NeoPHOEBE)

Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
PubMed 文献 · Eur J Cancer · 2017-09-17

NeoPHOEBE是一项新辅助II期随机双盲研究,评估pan-PI3K抑制剂buparlisib联合曲妥珠单抗和紫杉醇治疗HER2阳性乳腺癌的疗效与安全性。因肝毒性在入组50例(计划256例)后暂停招募;buparlisib组与安慰剂组pCR率相似(32.0% vs 40%;单侧P=0.811)。在ER+亚组中,buparlisib组ORR有升高趋势(68.8% vs 33.3%;P=0.053),Ki67显著下降(75% vs 26.7%;P=0.021)。

要点

  • 因肝毒性提前终止,仅入组50/256例,buparlisib联合方案可行性受限。
  • 总体pCR率buparlisib组32.0% vs 安慰剂组40%,无显著差异(单侧P=0.811)。
  • ER+亚组中buparlisib组ORR 68.8% vs 33.3%(P=0.053),Ki67下降75% vs 26.7%。

核心结论

  • 在HER2阳性早期乳腺癌中,将pan-PI3K抑制剂buparlisib加入紫杉烷-曲妥珠单抗方案不可行。
  • ER+、HER2+亚组中较高的ORR和Ki67下降提示PI3K靶向治疗在该亚组可能有潜在作用,可能值得用耐受性更好的第二代PI3K抑制剂进一步研究。

研究设计与样本

  • NeoPHOEBE为多中心、新辅助、II期、随机、双盲、安慰剂对照研究。
  • HER2+乳腺癌女性按PIK3CA突变状态随机分入两个独立队列,每个队列内按ER状态分层,接受buparlisib或安慰剂联合曲妥珠单抗(前6周),随后buparlisib或安慰剂联合曲妥珠单抗和紫杉醇。
  • 计划入组256例,实际入组50例后因肝毒性暂停招募;buparlisib组n=25,安慰剂组n=25;每组21例(84%)PIK3CA野生型,4例(16%)突变型。
  • 主要终点为病理完全缓解(pCR)率;关键次要终点为6周时客观缓解率(ORR);探索性终点为第15天中间活检中Ki67水平和肿瘤浸润淋巴细胞(TILs)变化。

主要发现

  • 总体pCR率buparlisib组32.0% vs 安慰剂组40%(单侧P=0.811),两组相似。
  • ER+亚组中,buparlisib组ORR 68.8% vs 安慰剂组33.3%(P=0.053),buparlisib组有升高趋势;交互作用P=0.03。
  • ER+亚组中,buparlisib组Ki67下降75% vs 安慰剂组26.7%(P=0.021),buparlisib组显著下降。

局限性

  • 原文明确因肝毒性在入组50/256例后暂停招募。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The Neoadjuvant PI3K inhibition in HER2 OverExpressing Breast cancEr (NeoPHOEBE) trial evaluated the efficacy and safety of buparlisib, a pan-phosphatidylinositol 3-kinase (PI3K) inhibitor, plus trastuzumab and paclitaxel as neoadjuvant treatment for human epidermal growth factor receptor-2 positive (HER2+) breast cancer. METHODS: NeoPHOEBE was a neoadjuvant, phase II, randomised, double-blind study. Women with HER2+ breast cancer were randomised within two independent cohorts by PIK3CA mutation status and, in each cohort stratified by oestrogen receptor (ER) status to receive buparlisib or placebo plus trastuzumab (first 6 weeks) followed by buparlisib or placebo with trastuzumab and paclitaxel. Primary end-point was pathological complete response (pCR) rate; key secondary end-point was objective response rate (ORR) at 6 weeks. Exploratory end-points were evaluation of Ki67 levels and change in tumour infiltrating lymphocytes (TILs) in intermediate biopsies at day 15. RESULTS: Recruitment was suspended mainly due to liver toxicity after enrolment of 50 of the planned 256 patients. In each arm (buparlisib n = 25; placebo n = 25) 21 patients (84%) had wild type PIK3CA and 4 patients (16%) had mutant PIK3CA. Overall, pCR rate was similar between buparlisib and placebo arms (32.0% versus 40%; one-sided P = 0.811). A trend towards higher ORR (68.8% versus 33.3%; P = 0.053) and a significant decrease in Ki67 (75% versus 26.7%; P = 0.021) was observed in buparlisib versus placebo arm in the ER+ subgroup (Pinteraction = 0.03). CONCLUSIONS: Addition of the pan-PI3K inhibitor buparlisib to taxane-trastuzumab-based therapy in HER2+ early breast cancer was not feasible. However, the higher ORR and Ki67 reduction in the ER+, HER2+ subgroup indicates a potential role for PI3K-targeted therapy in this setting and may warrant further investigation with better-tolerated second-generation PI3K inhibitors. TRIAL REGISTRATION IDENTIFIER: NCT01816594.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Loibl S, de la Pena L, Nekljudova V, et al. Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). Eur J Cancer. 2017. PMID: 28923573. doi:10.1016/j.ejca.2017.08.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。